Market research
003120.KO Ilsung Pharmaceuticals Co., Ltd
KO KRW Healthcare
Latest close
As of 30 Oct 2026
Test a moving-average rule with historical data.
Market facts
- Market cap
- 156B
- P/E ratio
- 28.3
- Analyst target
- Not available
- Dividend yield
- 5.5%
- Beta
- -0.21
Profile
Instrument facts
- Exchange
- KO
- Currency
- KRW
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- ISIN
- KR7003120003
- Market cap
- 156B
- P/E ratio
- 28.3
- Analyst target
- Not available
- Dividend yield
- 5.5%
- Beta
- -0.21
About
About Ilsung Pharmaceuticals Co., Ltd
Ilsung Is Co., Ltd. operates as a pharmaceutical company in South Korea. Its products include antibiotics, analgesics, muscle relaxants, antipyretic-analgesics, antihistamine, neuropsychiatric, neuromuscular blocker/ central muscle relaxants, anti-coagulants, probiotics, vaccine, medical equipment, circulatory system drugs, contrast agents, muscle relaxants, diabetes treatments, osteopathic, digestive system medicines, anti-virals, anti-emetics, respiratory treatments, adrenal cortical steroids, anesthetics, antipyretics, and cardiovascular system products. The company was formerly known as Ilsung Pharmaceuticals Co., Ltd. and changed its name to Ilsung Is Co., Ltd. in April 2024. Ilsung Is Co., Ltd. was founded in 1954 and is headquartered in Seoul, South Korea.
Research context
Ilsung Pharmaceuticals Co., Ltd appears in PyInvesting’s Korea Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- KRW
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the 003120.KO discussion.
5 years, 6 months ago
Ilsung Pharmaceuticals Co., Ltd is currently in a long term uptrend where the price is trading 2.8% above its 200 day moving average.
From a valuation standpoint, the stock is 63.8% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 3.1.
Ilsung Pharmaceuticals Co., Ltd's total revenue sank by 21.1% to $10B since the same quarter in the previous year.
Its net income has dropped by 38.4% to $2B since the same quarter in the previous year.
Finally, its free cash flow fell by 847.7% to $-6B since the same quarter in the previous year.
Based on the above factors, Ilsung Pharmaceuticals Co., Ltd gets an overall score of 2/5.